Core Insights - Mainz Biomed has announced a strategic partnership with labor team w ag to launch ColoAlert, a DNA-based colorectal cancer screening test in Switzerland, marking its first entry into the Swiss market [1][5] - The partnership aims to enhance early detection and prevention of colorectal cancer, which remains a significant health issue in Switzerland with thousands of new cases diagnosed annually [2][5] - This collaboration combines Mainz Biomed's expertise in DNA diagnostics with labor team's established laboratory services, providing a state-of-the-art screening solution [3][4] Company Overview - Mainz Biomed specializes in molecular genetic diagnostic solutions, with ColoAlert being its flagship product for early detection of colorectal cancer [6] - The company is also developing PancAlert, an early-stage pancreatic cancer screening test, and is pursuing FDA approval for its products in the US market [6] - Labor team w ag is one of Switzerland's leading private medical laboratories, established in 2001, and is known for its comprehensive laboratory services across the country [7][8] Market Implications - The introduction of ColoAlert aligns with the increasing demand for personalized healthcare solutions focused on early intervention and prevention [5] - The screening test will be available through labor team's extensive network of healthcare providers starting in spring 2025, potentially increasing participation rates in colorectal cancer screening [5] - This partnership positions both companies to contribute significantly to public health by improving access to reliable diagnostic tools for colorectal cancer [4][5]

Core Insights - Mainz Biomed's partner GANZIMMUN Diagnostics has launched the enhanced ColoAlert colorectal cancer screening test in Germany, coinciding with Colorectal Cancer Awareness Month in March [1][4] - The enhanced ColoAlert features advanced technology, including a proprietary DNA stabilizing buffer, allowing for accurate results across varying sample volumes [2] - The launch reflects a commitment to improving colorectal cancer prevention and detection through innovative and accessible diagnostics [3][6] Company Developments - The enhanced ColoAlert was first introduced in mid-2024 and is now available to patients, enhancing early detection capabilities for colorectal cancer [2][8] - Mainz Biomed is currently conducting a pivotal FDA clinical study for regulatory approval in the United States, indicating potential market expansion [8] - The company also has other product candidates, such as PancAlert, aimed at early-stage pancreatic cancer detection [8] Industry Context - The launch aligns with updated national screening guidelines in Germany, which now ensure equal access to screening for both men and women starting at age 50, addressing previous gender-based discrepancies [5] - The increased awareness of colorectal cancer screening is expected to drive broader participation in preventive measures within healthcare settings [5] - The collaborative effort between Mainz Biomed and GANZIMMUN highlights the importance of innovative diagnostics in the fight against colorectal cancer [6]

Core Points - Mainz Biomed NV has regained compliance with Nasdaq's minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market as of January 23, 2025 [1] - The company had previously confirmed compliance with the minimum bid price requirement, and is now fully compliant with all Nasdaq continued listing requirements [1] Company Overview - Mainz Biomed specializes in molecular genetic diagnostic solutions for early cancer detection, with its flagship product being ColoAlert, a non-invasive test for colorectal cancer [2] - ColoAlert is marketed in Europe and the UAE, and the company is conducting a pivotal FDA clinical study for US regulatory approval [2] - The product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test utilizing real-time PCR multiplex detection of molecular-genetic biomarkers in stool samples [2]

Study Overview - Mainz Biomed NV launches eAArly DETECT 2, a U S feasibility study to evaluate its next-generation colorectal cancer (CRC) test, integrating mRNA biomarkers, AI algorithms, and FIT test, targeting a population of approximately 2,000 average-risk patients [1] - The study aims to validate previous feasibility study results, which included both average-risk and identified-risk patients, and is expected to complete enrollment in the second half of 2025 with topline results reported by Q4 2025 [1][2] Study Objectives and Impact - The eAArly DETECT 2 study will evaluate the effectiveness of five novel mRNA biomarkers acquired from Sherbrooke University in 2022, which have shown unique ability to identify advanced adenomas and early-stage CRC [3] - The study aims to enhance product specifications by combining these biomarkers with Mainz Biomed's proprietary AI algorithm, potentially increasing diagnostic sensitivity and specificity for early-stage CRC [3] - Successful outcomes from the study will enable Mainz Biomed to finalize protocols for ReconAAsense, its U S pivotal study, scheduled to initiate in 2026 [2] Company Strategy and Vision - The launch of eAArly DETECT 2 is a significant milestone for Mainz Biomed, accelerating the timeline to evaluate biomarkers for inclusion in the U S pivotal study [3] - The company's next-generation CRC test aims to transform colorectal cancer screening by detecting cancerous polyps with high accuracy and potentially preventing the disease through early detection of precancerous adenomas [2][3] - Mainz Biomed's mission is to transform CRC screening practices and reduce global cancer mortality rates by enabling precise detection of advanced adenomas and early-stage CRC [3] Company Background - Mainz Biomed specializes in molecular genetics diagnostics for life-threatening conditions, with ColoAlert® as its flagship product, marketed in Europe and the UAE [4] - The company is conducting a pivotal FDA clinical study for U S regulatory approval of ColoAlert® and is developing PancAlert, an early-stage pancreatic cancer screening test [4]

Core Insights - Mainz Biomed has entered into an agreement with Quest Diagnostics to support the commercialization of its NextGen colorectal cancer screening test, ColoAlert, pending FDA approval [1][3] - The ColoAlert test utilizes PCR technology to detect colorectal cancer tumor DNA from stool samples, demonstrating promising sensitivity and specificity in preliminary studies [2] - The collaboration includes Quest providing clinical trial laboratory services for Mainz Biomed's ReconAAsense study, which will involve approximately 15,000 subjects across 150 sites in the U.S. to gather data for FDA validation [3] Industry Context - Colorectal cancer is the third most common cancer globally, with over 1.9 million new cases reported in 2020, highlighting a significant public health concern [4] - The U.S. Preventive Services Task Force recommends screening for colorectal cancer starting at age 45, yet about one-third of U.S. residents aged 50-75 have never been screened, representing a market opportunity exceeding $4 billion [4] - The introduction of alternative screening methods like stool DNA-FIT tests could help address the screening gap in the population [4]

Core Points - Mainz Biomed N.V. has successfully closed a follow-on offering of 1,367,521 units, generating approximately $8.0 million in gross proceeds [1] - Each unit was sold at an effective price of $5.85, which includes one ordinary share and two types of warrants [1] - The Class A and Class B warrants are both immediately exercisable at the same price and have different expiration conditions [1] Company Overview - Mainz Biomed specializes in molecular genetics diagnostics, focusing on early cancer detection [3] - The flagship product, ColoAlert®, is a non-invasive test for colorectal cancer, currently marketed in Europe [3] - The company is conducting a pivotal FDA clinical study for regulatory approval in the U.S. and is developing PancAlert, a pancreatic cancer screening test [3]

Core Viewpoint - Mainz Biomed N.V. announced a 1-for-40 reverse stock split effective December 3, focusing on early cancer detection, particularly colorectal cancer [1] Group 1: Collaboration and Product Development - Mainz Biomed entered a collaborative agreement with Thermo Fisher Scientific to jointly develop and commercialize a next-generation colorectal cancer screening product [1][2] - The collaboration will utilize Thermo Fisher's technologies to create proprietary assays for mRNA-based colorectal cancer screening tests [2] - The goal is to develop a home collection colorectal screening tool that effectively detects adenomas [3] Group 2: Financial Performance - In October, Mainz Biomed reported a 4% increase in revenue and a 32% decrease in operational losses for the first half of 2024, attributed to cost-reduction efforts [3] Group 3: Product Enhancements - Significant improvements were made to the ColoAlert product, which is available in Europe and select international markets [4] - The new proprietary buffer in ColoAlert reduces the need for additional sample submissions, speeding up result delivery [4] - ColoAlert now boasts the industry's lowest retesting rates, with screening outcomes delivered within two to three days of laboratory arrival [5] Group 4: Stock Performance - As of the publication date, MYNZ stock is down 13.09%, trading at $6.93 [6]

BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a 1-for-40 reverse stock split of its issued and outstanding shares. The reverse stock split was authorized by the Board of Directors of the Company pursuant to shareholder approval granted at its Extraordinary Shareholders Meeting on November 20, 2024. The reverse stock ...

Revenue increases 4% year over year while loss from operations decreases by 32% Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO showing groundbreaking performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Company highlights its path to success for 2025 BERKELEY, Calif. and MAINZ, Germany, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diag ...

Exhibit 99.2 Mainz Biomed N.V. Consolidated Statements of Financial Position (Unaudited) (Expressed in US Dollars) | | | | | December | | --- | --- | --- | --- | --- | | | | June 30, | | 31, | | | Note | 2024 | | 2023 | | ASSETS | | | | | | Current Assets | | | | | | Cash | | $ 977,764 | | $ 7,070,925 | | Trade and other receivables, net | 4 | 139,414 | | 93,555 | | Inventories | 5 | 520,531 | | 613,638 | | Prepaid expenses and other current assets | 6 | 751,994 | | 1,201,778 | | Total Current Assets | | 2, ...